(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/103712 A1

(51) International Patent Classification[7]: A61K 45/06, 39/395, 31/426, 31/427, A61P 35/00

(21) International Application Number: PCT/EP03/05988

(22) International Filing Date: 6 June 2003 (06.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/387,025	10 June 2002 (10.06.2002)	US
60/406,238	27 August 2002 (27.08.2002)	US
60/406,239	27 August 2002 (27.08.2002)	US
60/438,677	8 January 2003 (08.01.2003)	US
60/438,676	8 January 2003 (08.01.2003)	US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HOHNEKER, John, Arthur** [US/US]; 21 Hilltop Circle, Morristown, NJ 07960 (US). **MILLER, Julie, Ann** [US/US]; 28 Hamilton Court, Whippany, NJ 07981 (US). **ROTHERMEL, John, David** [US/US]; 46 School House Road, Randolph, NJ 07869 (US). **WARTMANN, Markus** [CH/CH]; Kornfeldstrasse 14, CH-4125 Riehen (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Proprety, CH-4002 Basel (CH).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF



(I)

(57) Abstract: The invention relates to a pharmaceutical combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosyl-methionine decarboxylase inhibitors; and (c) an epothilone derivative of formula (I), and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

WO 03/103712 A1